Page 34 - Stock Analysis
Shree Cement Q1: Profit nearly doubles, analysts stay cautiously optimistic
Brokerages offered a mixed yet constructive view on Shree Cement 's Q1 performance, highlighting improved realisations, expanding margins, and long-term growth plans.
 "Shree Cement Q1: Profit nearly doubles, analysts stay cautiously optimistic")
Logistics major Delhivery likely to gain from higher volumes, margins
While the core segments did well, the performance in the supply chain services and cross border businesses underperformed due to the exits from unprofitable contracts and weak seasonal demand
 "Logistics major Delhivery likely to gain from higher volumes, margins")
Should you stay invested in Tata Power post Q1? Here's what analysts say
Nuvama warned that Tata Power's current solar manufacturing margins may taper in the second half as captive supplies ramp up.
 "Should you stay invested in Tata Power post Q1? Here's what analysts say")
Explained: Why analysts raised Kaynes Tech stock target post Q1 results?
Kaynes Tech shares rose as much as 5 per cent in the intraday trade on Friday, hitting a high of ₹6,483 per share
 "Explained: Why analysts raised Kaynes Tech stock target post Q1 results?")
Dabur shares rise 3% as analysts flag positive outlook post Q1 results
Dabur shares rose 3 per cent after it reported a 2.8 per cent increase in net profit for the June quarter
 "Dabur shares rise 3% as analysts flag positive outlook post Q1 results")
Tata Consumer may find buffer in margins despite mixed Q1 results
Q1 results fell short of Street estimates. Strong growth in the company's core tea and salt businesses failed to offset the sluggish performance in its growth portfolio, dragging down overall numbers
 "Tata Consumer may find buffer in margins despite mixed Q1 results")
How Wockhardt's bet on multi-drug resistant infections is paying off
In India, Zaynich will be positioned as a third-line treatment, primarily for ICU patients when other antibiotics have failed
 "How Wockhardt's bet on multi-drug resistant infections is paying off")
Varun Beverages shares rise 10% in 2 days post Q2 results; upside left?
Most analysts have maintained their ratings on Varun Beverages' stock, while slightly increasing their share price target post Q2-2025 results. Check the latest targets and upside potential
 "Varun Beverages shares rise 10% in 2 days post Q2 results; upside left?")
L&T rises 4% on posting Q1 results; most brokerages raise target price
L&T shares rose 4.4 per cent in trade after the company reported healthy Q1 numbers; here's what brokerages suggest
 "L&T rises 4% on posting Q1 results; most brokerages raise target price")
TCS stock hits 33-month low; Jefferies, YES Securities' take on what's next
TCS shares extended their decline for the fourth consecutive session, slipping 4 per cent after it announced plans to lay off roughly 2 per cent of its global workforce
 "TCS stock hits 33-month low; Jefferies, YES Securities' take on what's next")
IndusInd Bank rises 2% on posting Q1 results; Should you buy, sell or hold?
IndusInd Bank Q1 results review: IndusInd Bank reported a 72 per cent decline in net profit; what's next?
 "IndusInd Bank rises 2% on posting Q1 results; Should you buy, sell or hold?")
Sell CDSL shares to invest in the NSDL IPO? Here's what analysts recommend
Notably, the public issue of NSDL will be an entirely offer-for-sale (OFS) of 50.14 million equity shares, with no fresh capital being raised by the company
 "Sell CDSL shares to invest in the NSDL IPO? Here's what analysts recommend")
TCS' decision to lay off nearly 12,000 employees may lift margins
Firm's operating margin has remained below target for five consecutive quarters
 "TCS' decision to lay off nearly 12,000 employees may lift margins")
Bank of Baroda stock volatile after mixed Q1 show; analysts decode numbers
Bank of Baroda shares fell over 2 per cent as analysts termed the lender's Q1 earnings as a mixed bag, with muted net profit growth
 "Bank of Baroda stock volatile after mixed Q1 show; analysts decode numbers")
Next US fix could stanch Cipla's Revlimid bleed amid pricing pressure
Generics pipeline starts to pulse as Advair, Symbicort, and Abraxane prepare to hit the vein
 "Next US fix could stanch Cipla's Revlimid bleed amid pricing pressure")
Why are investors selling Bajaj Finance shares post Q1? Stock falls 5%
Bajaj Finance shares nosedived on the BSE today as investors turned cautious on the near-term outlook post the NBFC's Q1 results. Read to find out investment strategy in the stock
 "Why are investors selling Bajaj Finance shares post Q1? Stock falls 5%")
Nestle shares slip 7% in two days of posting Q1; what should investors do?
Nestle India Q1 results review: Most brokerages have cut their target price on Nestle post Q1, on higher inflation concerns, and elevated depreciation/finance costs due to higher capital expenditure.
 "Nestle shares slip 7% in two days of posting Q1; what should investors do?")
Analysts stay bullish on Infosys after steady Q1 show; Should you buy in?
Backed by large deals, Infosys raised the lower end of its guidance to 1 per cent from nil growth it had guided a quarter earlier. Analysts reiterated their bullish calls
 "Analysts stay bullish on Infosys after steady Q1 show; Should you buy in?")
IEX tanks 23%: Brokerages decode what CERC's nod to 'market coupling' mean
IEX shares were locked at the lower circuit on the stock exchanges today as approval to market coupling norm will shift volumes to other competing exchanges, denting growth prospects of IEX
 "IEX tanks 23%: Brokerages decode what CERC's nod to 'market coupling' mean")
Weak demand outlook to weigh on sales, margins of Colgate Palmolive
Sentiment for the stock, which has shed 15 per cent over the past three months, continues to remain bearish given the weak demand outlook
 "Weak demand outlook to weigh on sales, margins of Colgate Palmolive")